董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Carl C. Dockery | 男 | Director | 60 | 128.88万美元 | 未持股 | 2023-10-12 |
| Abhinav Jian | 男 | Director | 32 | 未披露 | 未持股 | 2023-10-12 |
| Vivian H. Liu | 女 | Director | 61 | 未披露 | 未持股 | 2023-10-12 |
| Joshua R. Disbrow | 男 | Chairman and Chief Executive Officer | 47 | 70.80万美元 | 未持股 | 2023-10-12 |
| John A. Donofrio, Jr. | 男 | Director | 55 | 129.38万美元 | 未持股 | 2023-10-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Oki | 男 | Chief Financial Officer, Secretary and Treasurer | 54 | 52.28万美元 | 未持股 | 2023-10-12 |
| Greg Pyszczymuka | 男 | Chief Commercial Officer | 44 | 54.00万美元 | 未持股 | 2023-10-12 |
| Joshua R. Disbrow | 男 | Chairman and Chief Executive Officer | 47 | 70.80万美元 | 未持股 | 2023-10-12 |
董事简历
中英对照 | 中文 | 英文- Carl C. Dockery
-
Carl C. Dockery，他于2016年4月加入Aytu Biopharma, Inc.董事会。他的职业生涯始于1988年担任两个相关和非上市保险公司的保险执行官，以及职员和董事，包括担任Crossroads Insurance Co. Ltd. of Bermuda的秘书、Gulf Insurance Co. Ltd. of Grand Cayman的副总裁。20世纪90年代，他熟悉伦敦再保险市场，任职Lloyd’s、the London Underwriting Centre，代理各类再保险配售。他担任CytoDyn Inc.（OTCQB：CYDY，生物技术公司）的董事。他获得Southeastern University的人文文学学士学位。
Carl C. Dockery,joined Aytu Biopharma, Inc. Board of Directors in July 2016. He is a senior pharmaceutical executive with over 30 years of experience in the industry across a broad range of areas, including President, Chief Financial Officer, and Chief Operating Officer positions. Mr. Donofrio has significant finance experience in consolidated financial reporting, international accounting and internal controls, financial systems development and implementation, cost accounting, inventory management, supply chain, transfer pricing, budget and forecast planning, integration of mergers and acquisitions and business development. Since March 2022 Mr. Donofrio has served as Executive Vice President, Chief Operating Officer of Novan Inc., a publicly held specialty dermatology company, and as President of Novan Inc.'s wholly owned subsidiary EPI Health, a specialty pharmaceutical company commercializing products in the dermatology market. From March 2019 until its acquisition by Novan, Inc in March 2022, Mr. Donofrio served as EPI Health's President. Mr. Donofrio previously served as Chief Financial Officer and Head of Business Development at TrialCard from March of 2018 to March 2019. TrialCard is a technology-driven pharmaceutical services company providing patient access and support programs to the pharmaceutical and biotechnology industries. Prior to joining TrialCard, Mr. Donofrio was the Chief Financial Officer and Head of North American Business Development for Merz North America, or Merz, from August 2013 to March 2018. Merz is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurosciences in the United States and Canada. At Merz, Mr. Donofrio was accountable for financial performance, cost management, business development and strategic business planning and analysis for the finance organization in North America. Prior to joining Merz, Mr. Donofrio served as Vice President, Stiefel Global Finance, U.S. Specialty Business and Puerto Rico for Stiefel, a GlaxoSmithKline plc company from July 2009 to July 2013. In that role, Mr. Donofrio was responsible for the financial strategy, management reporting, and overall control framework for the Global Dermatology Business Unit. Mr. Donofrio served as a director of Vyrix from February 2014 to April 2015. Mr. Donofrio holds a degree in Accounting from North Carolina State University. - Carl C. Dockery，他于2016年4月加入Aytu Biopharma, Inc.董事会。他的职业生涯始于1988年担任两个相关和非上市保险公司的保险执行官，以及职员和董事，包括担任Crossroads Insurance Co. Ltd. of Bermuda的秘书、Gulf Insurance Co. Ltd. of Grand Cayman的副总裁。20世纪90年代，他熟悉伦敦再保险市场，任职Lloyd’s、the London Underwriting Centre，代理各类再保险配售。他担任CytoDyn Inc.（OTCQB：CYDY，生物技术公司）的董事。他获得Southeastern University的人文文学学士学位。
- Carl C. Dockery,joined Aytu Biopharma, Inc. Board of Directors in July 2016. He is a senior pharmaceutical executive with over 30 years of experience in the industry across a broad range of areas, including President, Chief Financial Officer, and Chief Operating Officer positions. Mr. Donofrio has significant finance experience in consolidated financial reporting, international accounting and internal controls, financial systems development and implementation, cost accounting, inventory management, supply chain, transfer pricing, budget and forecast planning, integration of mergers and acquisitions and business development. Since March 2022 Mr. Donofrio has served as Executive Vice President, Chief Operating Officer of Novan Inc., a publicly held specialty dermatology company, and as President of Novan Inc.'s wholly owned subsidiary EPI Health, a specialty pharmaceutical company commercializing products in the dermatology market. From March 2019 until its acquisition by Novan, Inc in March 2022, Mr. Donofrio served as EPI Health's President. Mr. Donofrio previously served as Chief Financial Officer and Head of Business Development at TrialCard from March of 2018 to March 2019. TrialCard is a technology-driven pharmaceutical services company providing patient access and support programs to the pharmaceutical and biotechnology industries. Prior to joining TrialCard, Mr. Donofrio was the Chief Financial Officer and Head of North American Business Development for Merz North America, or Merz, from August 2013 to March 2018. Merz is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurosciences in the United States and Canada. At Merz, Mr. Donofrio was accountable for financial performance, cost management, business development and strategic business planning and analysis for the finance organization in North America. Prior to joining Merz, Mr. Donofrio served as Vice President, Stiefel Global Finance, U.S. Specialty Business and Puerto Rico for Stiefel, a GlaxoSmithKline plc company from July 2009 to July 2013. In that role, Mr. Donofrio was responsible for the financial strategy, management reporting, and overall control framework for the Global Dermatology Business Unit. Mr. Donofrio served as a director of Vyrix from February 2014 to April 2015. Mr. Donofrio holds a degree in Accounting from North Carolina State University.
- Abhinav Jian
-
Abhinav Jian于2023年6月加入Aytu BioPharma, Inc.董事会。自2019年7月以来，贾恩一直担任Nantahala资本管理公司的分析师，专注于各个领域的投资，包括特种药品和仿制药。2015年至2017年，贾恩在另类资产管理公司Angelo，Gordon & Co.担任助理。在Angelo，Gordon & Co.，Jain先生专注于私人股本和结构性信贷投资。他于2012年毕业于麻省理工学院，获得化学-生物工程学士学位，并于2019年毕业于宾夕法尼亚大学沃顿商学院，获得金融和创业管理方面的工商管理硕士学位。
Abhinav Jian,joined Aytu Biopharma, Inc. Board of Directors in June 2023. Since July 2019, Mr. Jain has served as an Analyst at Nantahala Capital Management and is focused on investments in various sectors, including specialty and generic pharmaceuticals. From 2015-2017, Mr. Jain was an Associate at Angelo, Gordon & Co., an alternative asset manager. At Angelo, Gordon & Co., Mr. Jain focused on private equity and structured credit investments. He graduated from Massachusetts Institute of Technology in 2012 with an S.B. in Chemical-Biological Engineering and from The Wharton School of the University of Pennsylvania in 2019 with an M.B.A. with honors in Finance and Entrepreneurial Management. - Abhinav Jian于2023年6月加入Aytu BioPharma, Inc.董事会。自2019年7月以来，贾恩一直担任Nantahala资本管理公司的分析师，专注于各个领域的投资，包括特种药品和仿制药。2015年至2017年，贾恩在另类资产管理公司Angelo，Gordon & Co.担任助理。在Angelo，Gordon & Co.，Jain先生专注于私人股本和结构性信贷投资。他于2012年毕业于麻省理工学院，获得化学-生物工程学士学位，并于2019年毕业于宾夕法尼亚大学沃顿商学院，获得金融和创业管理方面的工商管理硕士学位。
- Abhinav Jian,joined Aytu Biopharma, Inc. Board of Directors in June 2023. Since July 2019, Mr. Jain has served as an Analyst at Nantahala Capital Management and is focused on investments in various sectors, including specialty and generic pharmaceuticals. From 2015-2017, Mr. Jain was an Associate at Angelo, Gordon & Co., an alternative asset manager. At Angelo, Gordon & Co., Mr. Jain focused on private equity and structured credit investments. He graduated from Massachusetts Institute of Technology in 2012 with an S.B. in Chemical-Biological Engineering and from The Wharton School of the University of Pennsylvania in 2019 with an M.B.A. with honors in Finance and Entrepreneurial Management.
- Vivian H. Liu
-
Vivian H. Liu 自2009年12月一直是Seelos Therapeutics, Inc.的执行副总裁和董事会主席，从2007年6月她曾担任公司董事，并从2007年6月-2009年12月是Seelos Therapeutics, Inc.代理行政总裁，2006年1月至2007年担任执行副总裁兼首席运营官，2004年1月至2005年12月担任首席财务官，从1999年至2004年1月担任代理首席财务官，从1995年9月到2005年12月担任财务主管，在1994年，Seelos Therapeutics, Inc.的过渡时期，刘女士担任首席执行官。从1985年至1994年刘女士是魁北克政府和加拿大众多公司产品配送技术转让和投资问题的商业和投资顾问。刘女士拥有南加州大学（the University of Southern California）文学士学位以及加州大学伯克利分校（the University of California Berkeley）国际金融系公共管理硕士学位。
Vivian H. Liu,joined Aytu Biopharma, Inc. Board of Directors in July 2022. Ms. Liu currently serves as Head of Corporate Affairs for PREMIA Holdings (HK) Limited, a developer of clinical-genomic oncology databases and service provider to pharmaceutical companies seeking to operate clinical trials throughout Asia. Prior to joining PREMIA, Ms. Liu served in various roles, including as a member of Board of Directors and President, Chief Executive Officer and Chief Financial Officer for Innovus Pharmaceuticals, Inc., a publicly listed consumer healthcare company acquired by Aytu BioPharma in February 2020. Prior to Innovus, she served as the President and Chief Executive Officer of FasTrack Pharmaceuticals, Inc. From 2017-2018, she served as the Chief Operating Officer and a member of the Board of Directors of Cesca Therapeutics, Inc. Previously, Vivian served as Managing Director of OxOnc Services Company, an oncology development company, and prior to that, Ms. Liu co-founded and served as President, Chief Executive Officer, and board director of NexMed, Inc., a drug development company which was later renamed Apricus BioSciences. Prior to her appointment as President of NexMed, Ms. Liu served in several executive capacities, including as Executive Vice President, Chief Operating Officer, Chief Financial Officer and Vice President of Corporate Affairs. Ms. Liu has an M.P.A. from the University of Southern California and a B.A. from the University of California, Berkeley. - Vivian H. Liu 自2009年12月一直是Seelos Therapeutics, Inc.的执行副总裁和董事会主席，从2007年6月她曾担任公司董事，并从2007年6月-2009年12月是Seelos Therapeutics, Inc.代理行政总裁，2006年1月至2007年担任执行副总裁兼首席运营官，2004年1月至2005年12月担任首席财务官，从1999年至2004年1月担任代理首席财务官，从1995年9月到2005年12月担任财务主管，在1994年，Seelos Therapeutics, Inc.的过渡时期，刘女士担任首席执行官。从1985年至1994年刘女士是魁北克政府和加拿大众多公司产品配送技术转让和投资问题的商业和投资顾问。刘女士拥有南加州大学（the University of Southern California）文学士学位以及加州大学伯克利分校（the University of California Berkeley）国际金融系公共管理硕士学位。
- Vivian H. Liu,joined Aytu Biopharma, Inc. Board of Directors in July 2022. Ms. Liu currently serves as Head of Corporate Affairs for PREMIA Holdings (HK) Limited, a developer of clinical-genomic oncology databases and service provider to pharmaceutical companies seeking to operate clinical trials throughout Asia. Prior to joining PREMIA, Ms. Liu served in various roles, including as a member of Board of Directors and President, Chief Executive Officer and Chief Financial Officer for Innovus Pharmaceuticals, Inc., a publicly listed consumer healthcare company acquired by Aytu BioPharma in February 2020. Prior to Innovus, she served as the President and Chief Executive Officer of FasTrack Pharmaceuticals, Inc. From 2017-2018, she served as the Chief Operating Officer and a member of the Board of Directors of Cesca Therapeutics, Inc. Previously, Vivian served as Managing Director of OxOnc Services Company, an oncology development company, and prior to that, Ms. Liu co-founded and served as President, Chief Executive Officer, and board director of NexMed, Inc., a drug development company which was later renamed Apricus BioSciences. Prior to her appointment as President of NexMed, Ms. Liu served in several executive capacities, including as Executive Vice President, Chief Operating Officer, Chief Financial Officer and Vice President of Corporate Affairs. Ms. Liu has an M.P.A. from the University of Southern California and a B.A. from the University of California, Berkeley.
- Joshua R. Disbrow
-
Joshua R. Disbrow，自2012年12月以来一直受雇于美国。加入Ampio之前，他从2007年5月到2012年10月担任乔木医药公司商业运作的副总裁，这是一家专业制药公司。他作为公司第二个全职员工加入了安娜，领导公司商业努力从开始到公司在2010年收购和增长超过1.27亿美元的净销售额。他领导的发展商业组织包括超过150人的销售、营销和其他商业功能。他花了近17年在制药、诊断和医疗设备行业，销售职位、市场营销、销售管理、商业运作和商业策略的责任也越来越大。加入Arbor之前，从2005年6月到2005年4月他担任Cyberonics区域销售经理，一家医疗设备公司专注于神经调节治疗。加入Cyberonics之前，他是北卡罗纳州的营销总监，一个体外诊断公司。他是Luoxis诊断公司的首席执行官，他持有维克森林大学的MBA学位和北卡罗莱纳州立大学管理学士学位。
Joshua R. Disbrow,has been employed by Aytu Biopharma, Inc. since April 16, 2015 and a member of Aytu Biopharma, Inc. Board of Directors since January 2016. Prior to the closing of the merger between Luoxis Diagnostics, Inc. and Vyrix Pharmaceuticals, Inc. that formed Aytu BioPharma, Mr. Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow jointly served as the Chief Operating Officer of Ampio Pharmaceuticals, Inc. ("Ampio") from December 2012 until April 2015. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals, LLC ("Arbor"), a specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as that company's second full-time employee. Mr. Disbrow led the company's commercial efforts from inception to the company's acquisition in 2010 and growth to over $127 million in net sales in 2011 and to over $250 million in net sales in 2012. By the time Mr. Disbrow departed Arbor in late 2012, he handled the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent over 26 years in the pharmaceutical, diagnostic, and medical device industries and has held positions of increasing responsibility in sales, sales management, marketing, commercial operations, commercial strategy, and business development. Prior to joining Arbor, Mr. Disbrow served as Regional Sales Manager with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience Inc., an in vitro diagnostics company. Mr. Disbrow holds an MBA from Wake Forest University School of Business and BS in Management from North Carolina State University. - Joshua R. Disbrow，自2012年12月以来一直受雇于美国。加入Ampio之前，他从2007年5月到2012年10月担任乔木医药公司商业运作的副总裁，这是一家专业制药公司。他作为公司第二个全职员工加入了安娜，领导公司商业努力从开始到公司在2010年收购和增长超过1.27亿美元的净销售额。他领导的发展商业组织包括超过150人的销售、营销和其他商业功能。他花了近17年在制药、诊断和医疗设备行业，销售职位、市场营销、销售管理、商业运作和商业策略的责任也越来越大。加入Arbor之前，从2005年6月到2005年4月他担任Cyberonics区域销售经理，一家医疗设备公司专注于神经调节治疗。加入Cyberonics之前，他是北卡罗纳州的营销总监，一个体外诊断公司。他是Luoxis诊断公司的首席执行官，他持有维克森林大学的MBA学位和北卡罗莱纳州立大学管理学士学位。
- Joshua R. Disbrow,has been employed by Aytu Biopharma, Inc. since April 16, 2015 and a member of Aytu Biopharma, Inc. Board of Directors since January 2016. Prior to the closing of the merger between Luoxis Diagnostics, Inc. and Vyrix Pharmaceuticals, Inc. that formed Aytu BioPharma, Mr. Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow jointly served as the Chief Operating Officer of Ampio Pharmaceuticals, Inc. ("Ampio") from December 2012 until April 2015. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals, LLC ("Arbor"), a specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as that company's second full-time employee. Mr. Disbrow led the company's commercial efforts from inception to the company's acquisition in 2010 and growth to over $127 million in net sales in 2011 and to over $250 million in net sales in 2012. By the time Mr. Disbrow departed Arbor in late 2012, he handled the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent over 26 years in the pharmaceutical, diagnostic, and medical device industries and has held positions of increasing responsibility in sales, sales management, marketing, commercial operations, commercial strategy, and business development. Prior to joining Arbor, Mr. Disbrow served as Regional Sales Manager with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience Inc., an in vitro diagnostics company. Mr. Disbrow holds an MBA from Wake Forest University School of Business and BS in Management from North Carolina State University.
- John A. Donofrio, Jr.
-
John A. Donofrio, Jr.，2014年2月以来，他成为Aytu Biopharma, Inc.董事会的成员。2013年8月以来，他担任Merz North America, Inc.（Merz）的首席财务官和北美业务拓展负责人。Merz是一个美国和加拿大美学、皮肤和神经科学的创新治疗方案的开发和商业化的专业医疗保健公司。在Merz时，他负责北美金融组织的财务业绩、成本管理、业务发展和战略业务规划和分析。加入Merz之前的2009年7月到2013年7月，他担任Stiefel Global Finance（美国专业业务）和Puerto Rico for Stiefel（葛兰素史克公司（GlaxoSmithKline plc company ））的副总裁。在此职位上，Donofurio先生负责全球皮肤病业务部门的财务战略、管理报告和总体控制框架。他是高级财务合伙人负责the GlaxoSmithKline美国专业业务单元。他在广泛的领域有超过22年的经验，包括合并财务报告、国际会计和内部控制，金融系统开发和实现，成本核算，库存管理、供应链、转让定价、预算和预测规划、整合并购和业务发展。他获得北卡罗利的北卡罗莱纳州立大学（ North Carolina State University）的会计学士学位。
John A. Donofrio, Jr. joined Aytu BioPharma, Inc.'s Board of Directors in July 2016. He is a senior pharmaceutical executive with 28 years of experience in industry including a broad range of areas in finance, including consolidated financial reporting, international accounting and internal controls, financial systems development and implementation, cost accounting, inventory management, supply chain, transfer pricing, budget and forecast planning, integration of mergers and acquisitions and business development. Since March 2019 he has served as the President of EPI Health, a privately-held specialty pharmaceutical company commercializing products in the dermatology market. He previously served as Chief Financial Officer at TrialCard from March of 2018 to March 2019. TrialCard is a technology-driven pharmaceutical services company providing patient access and support programs to the pharmaceutical and biotechnology industries. Prior to joining TrialCard, Mr. Donofrio was the Chief Financial Officer and Head of North American Business Development for Merz North America, or Merz, from August 2013 to March 2018. Merz is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurosciences in the United States and Canada. At Merz, Mr. Donofrio was accountable for financial performance, cost management, internal controls, business development and strategic business planning and analysis for the finance organization in North America. Prior to joining Merz, Mr. Donofrio served as Vice President, Stiefel Global Finance, U.S. Specialty Business and Puerto Rico for Stiefel, a GlaxoSmithKline plc company from July 2009 to July 2013. In that role, Mr. Donofrio was responsible for the financial strategy, management reporting, and overall control framework for the Global Dermatology Business Unit. He was also the Senior Finance Partner accountable for the U.S. Specialty Business Units of GlaxoSmithKline plc. Mr. Donofrio served as a director of Vyrix from February 2014 to April 2015. Mr. Donofrio holds a degree in Accounting from North Carolina State University. - John A. Donofrio, Jr.，2014年2月以来，他成为Aytu Biopharma, Inc.董事会的成员。2013年8月以来，他担任Merz North America, Inc.（Merz）的首席财务官和北美业务拓展负责人。Merz是一个美国和加拿大美学、皮肤和神经科学的创新治疗方案的开发和商业化的专业医疗保健公司。在Merz时，他负责北美金融组织的财务业绩、成本管理、业务发展和战略业务规划和分析。加入Merz之前的2009年7月到2013年7月，他担任Stiefel Global Finance（美国专业业务）和Puerto Rico for Stiefel（葛兰素史克公司（GlaxoSmithKline plc company ））的副总裁。在此职位上，Donofurio先生负责全球皮肤病业务部门的财务战略、管理报告和总体控制框架。他是高级财务合伙人负责the GlaxoSmithKline美国专业业务单元。他在广泛的领域有超过22年的经验，包括合并财务报告、国际会计和内部控制，金融系统开发和实现，成本核算，库存管理、供应链、转让定价、预算和预测规划、整合并购和业务发展。他获得北卡罗利的北卡罗莱纳州立大学（ North Carolina State University）的会计学士学位。
- John A. Donofrio, Jr. joined Aytu BioPharma, Inc.'s Board of Directors in July 2016. He is a senior pharmaceutical executive with 28 years of experience in industry including a broad range of areas in finance, including consolidated financial reporting, international accounting and internal controls, financial systems development and implementation, cost accounting, inventory management, supply chain, transfer pricing, budget and forecast planning, integration of mergers and acquisitions and business development. Since March 2019 he has served as the President of EPI Health, a privately-held specialty pharmaceutical company commercializing products in the dermatology market. He previously served as Chief Financial Officer at TrialCard from March of 2018 to March 2019. TrialCard is a technology-driven pharmaceutical services company providing patient access and support programs to the pharmaceutical and biotechnology industries. Prior to joining TrialCard, Mr. Donofrio was the Chief Financial Officer and Head of North American Business Development for Merz North America, or Merz, from August 2013 to March 2018. Merz is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurosciences in the United States and Canada. At Merz, Mr. Donofrio was accountable for financial performance, cost management, internal controls, business development and strategic business planning and analysis for the finance organization in North America. Prior to joining Merz, Mr. Donofrio served as Vice President, Stiefel Global Finance, U.S. Specialty Business and Puerto Rico for Stiefel, a GlaxoSmithKline plc company from July 2009 to July 2013. In that role, Mr. Donofrio was responsible for the financial strategy, management reporting, and overall control framework for the Global Dermatology Business Unit. He was also the Senior Finance Partner accountable for the U.S. Specialty Business Units of GlaxoSmithKline plc. Mr. Donofrio served as a director of Vyrix from February 2014 to April 2015. Mr. Donofrio holds a degree in Accounting from North Carolina State University.
高管简历
中英对照 | 中文 | 英文- Mark Oki
Mark Oki，自2022年1月起担任Aytu BioPharma, Inc.首席财务官，自2022年5月5日起担任Aytu BioPharma, Inc.秘书和财务主管。从2015年10月至2022年1月，Oki先生担任商业阶段制药公司Vivus LLC（原Vivus Inc.）的首席财务官。截至2020年12月，Vivus是一家在纳斯达克上市的公司。从2006年4月至2015年10月，Oki先生曾在上市的专业制药公司Alexza Pharmaceuticals, Inc.担任多个职位，最近的职务是高级副总裁、财务、首席财务官和秘书。在Alexza之前，Oki先生在生命科学公司Pharmacyclics，Inc.和因塞特医疗基因组学公司（现为因塞特医疗公司）担任越来越重要的职务。Oki先生的职业生涯始于德勤会计师事务所（Deloitte & Touche，LLP，现为德勤）。Oki先生获得工商管理-会计学学位，并以优异成绩毕业于圣何塞州立大学，是一名注册会计师（非在职）。
Mark Oki,has served as Aytu Biopharma, Inc. Chief Financial Officer since January 2022 and as Aytu Biopharma, Inc. Secretary and Treasurer since May 5, 2022. From October 2015 through January 2022, Mr. Oki served as Chief Financial Officer of Vivus LLC, (formerly Vivus Inc.) a commercial-stage pharmaceutical company. Vivus was a Nasdaq listed company up to December 2020. From April 2006 to October 2015, Mr. Oki held several positions at Alexza Pharmaceuticals, Inc., a publicly listed specialty pharmaceutical company, most recently as Senior Vice President, Finance, Chief Financial Officer and Secretary. Before Alexza, Mr. Oki held roles of increasing responsibility at life science companies, Pharmacyclics, Inc. and Incyte Genomics, Inc. (now Incyte Corporation). Mr. Oki began his career in public accounting at Deloitte & Touche, LLP (now Deloitte). Mr. Oki received his degree in Business Administration – Accounting and graduated with honors from San Jose State University and is a Certified Public Accountant (inactive).- Mark Oki，自2022年1月起担任Aytu BioPharma, Inc.首席财务官，自2022年5月5日起担任Aytu BioPharma, Inc.秘书和财务主管。从2015年10月至2022年1月，Oki先生担任商业阶段制药公司Vivus LLC（原Vivus Inc.）的首席财务官。截至2020年12月，Vivus是一家在纳斯达克上市的公司。从2006年4月至2015年10月，Oki先生曾在上市的专业制药公司Alexza Pharmaceuticals, Inc.担任多个职位，最近的职务是高级副总裁、财务、首席财务官和秘书。在Alexza之前，Oki先生在生命科学公司Pharmacyclics，Inc.和因塞特医疗基因组学公司（现为因塞特医疗公司）担任越来越重要的职务。Oki先生的职业生涯始于德勤会计师事务所（Deloitte & Touche，LLP，现为德勤）。Oki先生获得工商管理-会计学学位，并以优异成绩毕业于圣何塞州立大学，是一名注册会计师（非在职）。
- Mark Oki,has served as Aytu Biopharma, Inc. Chief Financial Officer since January 2022 and as Aytu Biopharma, Inc. Secretary and Treasurer since May 5, 2022. From October 2015 through January 2022, Mr. Oki served as Chief Financial Officer of Vivus LLC, (formerly Vivus Inc.) a commercial-stage pharmaceutical company. Vivus was a Nasdaq listed company up to December 2020. From April 2006 to October 2015, Mr. Oki held several positions at Alexza Pharmaceuticals, Inc., a publicly listed specialty pharmaceutical company, most recently as Senior Vice President, Finance, Chief Financial Officer and Secretary. Before Alexza, Mr. Oki held roles of increasing responsibility at life science companies, Pharmacyclics, Inc. and Incyte Genomics, Inc. (now Incyte Corporation). Mr. Oki began his career in public accounting at Deloitte & Touche, LLP (now Deloitte). Mr. Oki received his degree in Business Administration – Accounting and graduated with honors from San Jose State University and is a Certified Public Accountant (inactive).
- Greg Pyszczymuka
Greg Pyszczymuka，自2022年1月起担任Aytu BioPharma, Inc.首席商务官。在加入公司之前，在2021年3月公司与Neos治疗合并完成时，Greg Pyszczymuka自2020年6月起担任Neos治疗商务副总裁。他曾于2018年11月至2020年6月担任Neos商业战略与市场准入副总裁，并担任渠道战略与准入项目执行总监。在加入Neos之前，Greg在15年的职业生涯中担任过越来越重要的职务，包括销售管理、品牌管理、渠道战略、管理市场和新产品规划。格雷格最近从Aqua Pharmaceuticals（一家Almirall公司）加入Neos，之前曾在Iroko Pharmaceuticals、Zogenix和远藤制药工作。他拥有罗格斯大学的学士学位和阿尔戈西大学的工商管理硕士学位。
Greg Pyszczymuka,has served as Aytu Biopharma, Inc. Chief Commercial Officer since January 2022. Prior to joining the Company, at the closing of the company's merger with Neos Therapeutics in March 2021, Greg Pyszczymuka served as Vice President, Commercial at Neos Therapeutics since June 2020. He previously served as Vice President, Commercial Strategy & Market Access at Neos from November 2018 to June 2020, and as Executive Director of Channel Strategy & Access Programs. Prior to joining Neos, Greg had served in roles of increasing responsibility over a 15-year career including sales management, brand management, channel strategy, managed markets and new products planning. Greg joined Neos most recently from Aqua Pharmaceuticals (an Almirall company), and previously was with Iroko Pharmaceuticals, Zogenix, and Endo Pharmaceuticals. He holds a B.S. from Rutgers University and an M.B.A. from Argosy University.- Greg Pyszczymuka，自2022年1月起担任Aytu BioPharma, Inc.首席商务官。在加入公司之前，在2021年3月公司与Neos治疗合并完成时，Greg Pyszczymuka自2020年6月起担任Neos治疗商务副总裁。他曾于2018年11月至2020年6月担任Neos商业战略与市场准入副总裁，并担任渠道战略与准入项目执行总监。在加入Neos之前，Greg在15年的职业生涯中担任过越来越重要的职务，包括销售管理、品牌管理、渠道战略、管理市场和新产品规划。格雷格最近从Aqua Pharmaceuticals（一家Almirall公司）加入Neos，之前曾在Iroko Pharmaceuticals、Zogenix和远藤制药工作。他拥有罗格斯大学的学士学位和阿尔戈西大学的工商管理硕士学位。
- Greg Pyszczymuka,has served as Aytu Biopharma, Inc. Chief Commercial Officer since January 2022. Prior to joining the Company, at the closing of the company's merger with Neos Therapeutics in March 2021, Greg Pyszczymuka served as Vice President, Commercial at Neos Therapeutics since June 2020. He previously served as Vice President, Commercial Strategy & Market Access at Neos from November 2018 to June 2020, and as Executive Director of Channel Strategy & Access Programs. Prior to joining Neos, Greg had served in roles of increasing responsibility over a 15-year career including sales management, brand management, channel strategy, managed markets and new products planning. Greg joined Neos most recently from Aqua Pharmaceuticals (an Almirall company), and previously was with Iroko Pharmaceuticals, Zogenix, and Endo Pharmaceuticals. He holds a B.S. from Rutgers University and an M.B.A. from Argosy University.
- Joshua R. Disbrow
Joshua R. Disbrow，自2012年12月以来一直受雇于美国。加入Ampio之前，他从2007年5月到2012年10月担任乔木医药公司商业运作的副总裁，这是一家专业制药公司。他作为公司第二个全职员工加入了安娜，领导公司商业努力从开始到公司在2010年收购和增长超过1.27亿美元的净销售额。他领导的发展商业组织包括超过150人的销售、营销和其他商业功能。他花了近17年在制药、诊断和医疗设备行业，销售职位、市场营销、销售管理、商业运作和商业策略的责任也越来越大。加入Arbor之前，从2005年6月到2005年4月他担任Cyberonics区域销售经理，一家医疗设备公司专注于神经调节治疗。加入Cyberonics之前，他是北卡罗纳州的营销总监，一个体外诊断公司。他是Luoxis诊断公司的首席执行官，他持有维克森林大学的MBA学位和北卡罗莱纳州立大学管理学士学位。
Joshua R. Disbrow,has been employed by Aytu Biopharma, Inc. since April 16, 2015 and a member of Aytu Biopharma, Inc. Board of Directors since January 2016. Prior to the closing of the merger between Luoxis Diagnostics, Inc. and Vyrix Pharmaceuticals, Inc. that formed Aytu BioPharma, Mr. Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow jointly served as the Chief Operating Officer of Ampio Pharmaceuticals, Inc. ("Ampio") from December 2012 until April 2015. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals, LLC ("Arbor"), a specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as that company's second full-time employee. Mr. Disbrow led the company's commercial efforts from inception to the company's acquisition in 2010 and growth to over $127 million in net sales in 2011 and to over $250 million in net sales in 2012. By the time Mr. Disbrow departed Arbor in late 2012, he handled the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent over 26 years in the pharmaceutical, diagnostic, and medical device industries and has held positions of increasing responsibility in sales, sales management, marketing, commercial operations, commercial strategy, and business development. Prior to joining Arbor, Mr. Disbrow served as Regional Sales Manager with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience Inc., an in vitro diagnostics company. Mr. Disbrow holds an MBA from Wake Forest University School of Business and BS in Management from North Carolina State University.- Joshua R. Disbrow，自2012年12月以来一直受雇于美国。加入Ampio之前，他从2007年5月到2012年10月担任乔木医药公司商业运作的副总裁，这是一家专业制药公司。他作为公司第二个全职员工加入了安娜，领导公司商业努力从开始到公司在2010年收购和增长超过1.27亿美元的净销售额。他领导的发展商业组织包括超过150人的销售、营销和其他商业功能。他花了近17年在制药、诊断和医疗设备行业，销售职位、市场营销、销售管理、商业运作和商业策略的责任也越来越大。加入Arbor之前，从2005年6月到2005年4月他担任Cyberonics区域销售经理，一家医疗设备公司专注于神经调节治疗。加入Cyberonics之前，他是北卡罗纳州的营销总监，一个体外诊断公司。他是Luoxis诊断公司的首席执行官，他持有维克森林大学的MBA学位和北卡罗莱纳州立大学管理学士学位。
- Joshua R. Disbrow,has been employed by Aytu Biopharma, Inc. since April 16, 2015 and a member of Aytu Biopharma, Inc. Board of Directors since January 2016. Prior to the closing of the merger between Luoxis Diagnostics, Inc. and Vyrix Pharmaceuticals, Inc. that formed Aytu BioPharma, Mr. Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow jointly served as the Chief Operating Officer of Ampio Pharmaceuticals, Inc. ("Ampio") from December 2012 until April 2015. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals, LLC ("Arbor"), a specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as that company's second full-time employee. Mr. Disbrow led the company's commercial efforts from inception to the company's acquisition in 2010 and growth to over $127 million in net sales in 2011 and to over $250 million in net sales in 2012. By the time Mr. Disbrow departed Arbor in late 2012, he handled the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent over 26 years in the pharmaceutical, diagnostic, and medical device industries and has held positions of increasing responsibility in sales, sales management, marketing, commercial operations, commercial strategy, and business development. Prior to joining Arbor, Mr. Disbrow served as Regional Sales Manager with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience Inc., an in vitro diagnostics company. Mr. Disbrow holds an MBA from Wake Forest University School of Business and BS in Management from North Carolina State University.